200 related articles for article (PubMed ID: 25537909)
21. Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Yasuoka H; Kodama R; Hirokawa M; Takamura Y; Miyauchi A; Inagaki M; Sanke T; Nakamura Y
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1857-61. PubMed ID: 21880798
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
[No Abstract] [Full Text] [Related]
23. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
25. [Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma].
Liang QC; Wei QY; Fan SQ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):414-6, 419. PubMed ID: 16859137
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
27. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma.
Vasileiadis I; Boutzios G; Charitoudis G; Koukoulioti E; Karatzas T
Ann Surg Oncol; 2014 Aug; 21(8):2725-32. PubMed ID: 24595799
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
29. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
[TBL] [Abstract][Full Text] [Related]
30. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
31. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
[TBL] [Abstract][Full Text] [Related]
32. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
33. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder.
von Hardenberg J; Martini T; Knauer A; Ströbel P; Becker A; Herrmann E; Schubert C; Steidler A; Bolenz C
Urol Oncol; 2014 Jan; 32(1):54.e9-17. PubMed ID: 24360666
[TBL] [Abstract][Full Text] [Related]
34. Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.
Chen X; Wu W; Chen X; Gong X
Tumour Biol; 2016 May; 37(5):6519-26. PubMed ID: 26637226
[TBL] [Abstract][Full Text] [Related]
35. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
[TBL] [Abstract][Full Text] [Related]
36. [Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma].
Zhao GG; Xiang XJ; He YJ
Ai Zheng; 2007 Jan; 26(1):90-5. PubMed ID: 17222375
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
38. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer.
Bogos K; Renyi-Vamos F; Dobos J; Kenessey I; Tovari J; Timar J; Strausz J; Ostoros G; Klepetko W; Ankersmit HJ; Lang G; Hoda MA; Nierlich P; Dome B
Clin Cancer Res; 2009 Mar; 15(5):1741-6. PubMed ID: 19240177
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
40. Hashimoto's thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value?
Divani SN; Kalodimos GP; Lioupis MA; Syrmos NC
Hell J Nucl Med; 2016; 19(3):250-253. PubMed ID: 27824965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
